Key Takeaways
- • The FTC settled its antitrust case against U.S. Anesthesia Partners (USAP), a private equity portfolio company that consolidated over a dozen anesthesiology practices across Texas, involving approximately 1,000 doctors and 750 nurses.
- • The settlement terms remain confidential pending USAP's execution of remedial measures designed to restore competitive market structure in Texas anesthesia services, with the FTC reserving the right to resume litigation if the company fails to comply.
- • Welsh, Carson, Anderson & Stowe, the private equity firm that created USAP, previously settled with the FTC after successfully challenging claims against it in court, narrowing the final settlement scope to the operating company alone.
- • This case represents a significant FTC enforcement action under the Biden administration targeting private equity rollup strategies—the acquisition of multiple small competitors within a single industry to consolidate market power and raise prices.
Summary
The Federal Trade Commission has reached a settlement to conclude its antitrust case against U.S. Anesthesia Partners, a private equity-backed rollup that acquired numerous anesthesiology practices throughout Texas. The settlement was formalized through court filings on April 23, 2026, marking a notable outcome in the agency's intensifying scrutiny of private equity consolidation strategies.
The FTC's original complaint centered on USAP's systematic acquisition of competing anesthesia practices across Texas, which the agency alleged enabled the company to monopolize local anesthesia services markets and raise prices for hospital and surgical center clients. The rollup encompassed over a dozen individual practices, collectively representing approximately 1,000 anesthesiologists and 750 nurses. Welsh, Carson, Anderson & Stowe, the private equity firm that established and controlled USAP, was initially included in the lawsuit but secured dismissal of claims against it, leaving the operating company as the primary defendant.
Under the settlement agreement, USAP has committed to remedial actions intended to restore competitive market structure in Texas anesthesia services. However, the specific terms of the settlement remain confidential "to facilitate the negotiations USAP must undertake," according to FTC statements. The agency indicated that the agreement aligns with "longstanding FTC settlement best practices" and explicitly reserved the right to resume litigation if USAP fails to fully execute the settlement obligations.
The case carries broader implications for private equity market participants and institutional investors evaluating consolidation strategies. The FTC's enforcement action underscores heightened regulatory scrutiny of rollup acquisition models—where financial sponsors purchase multiple small competitors to create scale and pricing power—signaling that antitrust regulators will challenge such strategies when they demonstrably reduce competition and elevate consumer costs. Private equity firms monitoring this settlement will likely await full disclosure of USAP's remedial obligations to assess compliance risks and adjust future consolidation strategies accordingly.
The FTC's original complaint centered on USAP's systematic acquisition of competing anesthesia practices across Texas, which the agency alleged enabled the company to monopolize local anesthesia services markets and raise prices for hospital and surgical center clients. The rollup encompassed over a dozen individual practices, collectively representing approximately 1,000 anesthesiologists and 750 nurses. Welsh, Carson, Anderson & Stowe, the private equity firm that established and controlled USAP, was initially included in the lawsuit but secured dismissal of claims against it, leaving the operating company as the primary defendant.
Under the settlement agreement, USAP has committed to remedial actions intended to restore competitive market structure in Texas anesthesia services. However, the specific terms of the settlement remain confidential "to facilitate the negotiations USAP must undertake," according to FTC statements. The agency indicated that the agreement aligns with "longstanding FTC settlement best practices" and explicitly reserved the right to resume litigation if USAP fails to fully execute the settlement obligations.
The case carries broader implications for private equity market participants and institutional investors evaluating consolidation strategies. The FTC's enforcement action underscores heightened regulatory scrutiny of rollup acquisition models—where financial sponsors purchase multiple small competitors to create scale and pricing power—signaling that antitrust regulators will challenge such strategies when they demonstrably reduce competition and elevate consumer costs. Private equity firms monitoring this settlement will likely await full disclosure of USAP's remedial obligations to assess compliance risks and adjust future consolidation strategies accordingly.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.